Jon Badiola

Jon Badiola

Auto-generated profile, based on publicly available information

Jon Badiola

Department of Hematology and Hemotherapy, Hospital Universitario Virgen de las Nieves, Granada, Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JEJohanna M. Eberhard
Johanna M. Eberhard
MAMathieu Angin
Mathieu Angin
Caroline PassaesCaroline Passaes
Caroline Passaes
MSMaria Salgado
Maria Salgado
VMValerie Monceaux
Valerie Monceaux
ASAsier Sáez-Cirión
Asier Sáez-Cirión
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only medical intervention that has led to an HIV cure. Whereas the HIV reservoir sharply decreases after allo-HSCT, the dynamics of the T cell reconstitution has not been comprehensively described. We analyzed the activation and differentiation of CD4+ and CD8+ T cells, and the breadth and quality of HIV- and CMV-specific CD8+ T cell responses in 16 patients with HIV who underwent allo-HSCT (including five individuals who received cells from CCR5Δ32/Δ32 donors) to treat their underlying hematological malignancy and who remained on antiretroviral therapy (ART). We found that reconstitution of the T cell compartment after allo-HSCT was slow and heterogeneous with an initial expansion of activated CD4+ T cells that preceded the expansion of CD8+ T cells. Although HIV-specific CD8+ T cells disappeared immediately after allo-HSCT, weak HIV-specific CD8+ T cell responses were detectable several weeks after transplant and could still be detected at the time of full T cell chimerism, indicating that de novo priming, and hence antigen exposure, occurred during the time of T cell expansion. These HIV-specific T cells had limited functionality compared with CMV-specific CD8+ T cells and persisted years after allo-HSCT. In conclusion, immune reconstitution was slow, heterogeneous, and incomplete and coincided with de novo detection of weak HIV-specific T cell responses. The initial short phase of high T cell activation, in which HIV antigens were present, may constitute a window of vulnerability for the reseeding of viral reservoirs, emphasizing the importance of maintaining ART directly after allo-HSCT.

1 April 2021 in Enfermedades Infecciosas y Microbiología Clínica
Verified
Journal Article
Closed access
JBJon Badiola
Jon Badiola
LMLeopoldo Muñoz-Medina
Leopoldo Muñoz-Medina
JCJosé Luis Callejas
José Luis Callejas
ADAlicia Delgado-García
Alicia Delgado-García
MJManuel Jurado
Manuel Jurado
JHJosé Hernández-Quero
José Hernández-Quero

16 July 2020 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
JSJ. M. Sánchez-Maldonado
J. M. Sánchez-Maldonado
DCD. Campa
D. Campa
JSJ. Springer
J. Springer
JBJ. Badiola
J. Badiola
YNYasmeen Niazi
Yasmeen Niazi
Juan SainzJuan Sainz
Juan Sainz
The purpose of this study was to conduct a two-stage case control association study including 654 acute myeloid leukaemia (AML) patients and 3477 controls ascertained through the NuCLEAR consortium to evaluate the effect of 27 immune-related single nucleotide polymorphisms (SNPs) on AML risk. In a pooled analysis of cohort studies, we found that carriers of the IL13rs1295686A/A genotype had an increased risk of AML (PCorr = 0.0144) whereas carriers of the VEGFArs25648T allele had a decreased risk of developing the disease (PCorr = 0.00086). In addition, we found an association of the IL8rs2227307 SNP with a decreased risk of developing AML that remained marginally significant after multiple testing (PCorr = 0.072). Functional experiments suggested that the effect of the IL13rs1295686 SNP on AML risk might be explained by its role in regulating IL1Ra secretion that modulates AML blast proliferation. Likewise, the protective effect of the IL8rs2227307 SNP might be mediated by TLR2-mediated immune responses that affect AML blast viability, proliferation and chemorresistance. Despite the potential interest of these results, additional functional studies are still warranted to unravel the mechanisms by which these variants modulate the risk of AML. These findings suggested that IL13, VEGFA and IL8 SNPs play a role in modulating AML risk.

15 December 2018 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
JBJon Badiola
Jon Badiola
NNNavarrete-Navarrete Navarrete Nuria
Navarrete-Navarrete Navarrete Nuria
JSJosé Mario Sabio
José Mario Sabio

17 May 2020 in Medicina Clinica
Verified
Journal Article
Closed access
EJElena María Gámez Jiménez
Elena María Gámez Jiménez
JBJulia Muñoz Ballester
Julia Muñoz Ballester
JBJon Badiola
Jon Badiola

1 June 2015
Verified
Journal Article
Closed access
DVDavid Vinuesa
David Vinuesa
VRVioleta Ramos
Violeta Ramos
APAlejandro Peña
Alejandro Peña
MRMaria Ruiz-Ruigómez
Maria Ruiz-Ruigómez
JBJon Badiola
Jon Badiola
JPJorge Parra-Ruiz
Jorge Parra-Ruiz